# A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies

> **NCT02623439** · PHASE2 · TERMINATED · sponsor: **University of California, San Diego** · enrollment: 10 (actual)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant

## Key facts

- **NCT ID:** NCT02623439
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09-21
- **Primary completion:** 2016-05-12
- **Final completion:** 2023-01-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Toxicity
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02623439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02623439, "A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT02623439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*